FDA accepts Unicycive's resubmission for kidney disease drug OLC

The FDA has accepted Unicycive Therapeutics' resubmission of its New Drug Application for oxylanthanum carbonate and set a March 25, 2027 PDUFA target date. The decision keeps the company's dialysis-focused phosphate binder in play after a prior complete response letter in June 2026.

Why it matters: - Oxylanthanum carbonate, or OLC, is Unicycive Therapeutics' lead drug candidate for hyperphosphatemia in patients with chronic kidney disease on dialysis. - FDA acceptance of the resubmission moves the program back into active review and gives Unicycive a new regulatory timeline. - A potential approval would add another treatment option for patients who need daily phosphate control and may benefit from a lower pill burden.

What happened: - The FDA accepted Unicycive Therapeutics' resubmission of its New Drug Application for OLC on Oct. 21, 2026. - The agency assigned a Prescription Drug User Fee Act target action date of March 25, 2027. - The FDA classified the resubmission as Class II, which carries a six-month review period from the resubmission date. - Unicycive resubmitted the NDA after receiving a Complete Response Letter in June 2026.

The details: - The resubmission includes chemistry, manufacturing and controls data from a new third-party drug product manufacturing vendor. - Unicycive said the new vendor's facility was last inspected by the FDA in March 2024 and received a No Action Indicated status. - The company said it does not know whether the FDA will conduct a pre-approval inspection of the new vendor. - If the original third-party manufacturer is inspected soon and found to comply with current Good Manufacturing Practice, Unicycive plans to seek FDA alignment on a shorter approval timeline. - The second Complete Response Letter cited deficiencies previously identified at the original third-party drug product manufacturer. - The FDA had not been able to re-inspect that original manufacturer during the prior review. - The NDA is supported by three clinical studies, multiple preclinical studies and chemistry, manufacturing and controls data. - The clinical package included a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers and a tolerability study in CKD patients on dialysis. - The FDA did not raise concerns about OLC's preclinical or clinical data, including safety data, in the original NDA submission. - Unicycive is pursuing FDA approval through the 505(b)(2) pathway. - OLC has issued composition-of-matter patents with exclusivity until 2031, with potential patent term extension until 2035.

Between the lines: - The regulatory issue appears centered on manufacturing and inspection timing, not on the drug's clinical data. - The company's path forward now depends heavily on whether the FDA inspects the manufacturing sites and whether those inspections clear the remaining quality-control questions. - A faster approval timeline remains possible, but only if the FDA reviews the original vendor quickly and finds no cGMP problems.

What's next: - The FDA will continue reviewing the resubmitted NDA ahead of the March 25, 2027 PDUFA date. - Any pre-approval inspection of the new third-party vendor would be at the FDA's discretion. - The timing and outcome of any inspection of the original third-party vendor will be determined by the FDA. - Unicycive will keep working toward potential approval for patients with CKD on dialysis who need additional hyperphosphatemia treatment options.

The bottom line: - Unicycive has cleared an important regulatory hurdle, but final approval still hinges on manufacturing review and FDA inspection decisions.